A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

NCT03668496 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer Squamous Cell
Lung Cancer Stage IV
PD-1 Antibody
Chemotherapy Effect

Interventions

DRUG: SHR-1210
DRUG: The placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.